Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + pertuzumab + toripalimab
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This drug is a **combination therapy of three agents**: **disitamab vedotin** (a HER2-targeted antibody-drug conjugate), **pertuzumab** (an anti-HER2 monoclonal antibody), and **toripalimab** (a PD-1 immune checkpoint inhibitor). Disitamab vedotin delivers a potent cytotoxic agent to HER2-expressing cells via an antibody-drug conjugate mechanism; pertuzumab blocks the dimerization of HER2 with other HER family members, inhibiting cell growth signaling; toripalimab releases immune inhibition by blocking PD-1, enhancing T-cell mediated anti-tumor activity. This triple regimen is being investigated in clinical trials for **HER2-positive breast cancer**, **muscle-invasive bladder cancer**, and potentially other HER2-driven or immune-responsive tumors[1][2][5][6].
- Other names
- disitamab vedotinpertuzumabtoripalimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on disitamab vedotin + pertuzumab + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + pertuzumab + toripalimab.